SOURCE: BrainStorm Cell Therapeutics, Inc.

September 30, 2014 06:52 ET

BrainStorm Completes Uplisting to the NASDAQ Capital Market

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Sep 30, 2014) - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market, and will commence trading on the NASDAQ Capital Market when trading begins on September 30, 2014.

"We are so happy to bring BrainStorm's common stock to NASDAQ. This is an important step in BrainStorm's corporate development. The uplisting of the common stock to a national securities exchange should enhance the awareness of the important work BrainStorm is doing with adult stem cell technologies in the treatment of neurodegenerative diseases," said Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm.

BrainStorm's common shares will trade under the ticker symbol "BCLI" when trading on Nasdaq and will no longer temporarily be quoted as "BCLID" effective September 30, 2014. This modifies BrainStorm's previous announcement that from September 16, 2014 until October 14, 2014 their shares would be quoted as "BCLID" in order to designate the recent one (1) for fifteen (15) reverse split of BrainStorm's issued and outstanding common stock. 

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contact Information